Development of an inhibitor in a child with severe hemophilia B: treatment with immunosuppression and an extended desensitization protocol

Development of neutralizing alloantibodies in hemophilia B is a less common, but clinically challenging phenomenon. Novel therapeutics for hemophilia B have recently been developed and reports of clinical experience with these agents outside of clinical trials are needed. We report development of an